JAMA Oncology<\/a>, Paolo Tarantino, MD, PhD, and colleagues evaluated the 5-year outcomes of neoadjuvant THP for patients with ERBB2-positive breast cancer. They also assessed the ctDNA dynamics to determine whether ctDNA monitoring can provide a complementary measure of treatment response.<\/p>\nParticipants (n=98) included those with stage II to III ERBB2-positive breast cancer receiving neoadjuvant THP for 12 weeks. Ultrasensitive ctDNA analyses were performed for the 57 participants who had available tumor tissue and serial plasma samples.<\/p>\n
The main outcomes included 5-year event-free survival, recurrence-free interval (RFI), distant RFI, and overall survival. Results showed that with a median follow-up of 5.2 years (interquartile range, 5.0-5.4 years), the 5-year event-free survival was 99% (95% CI, 97%-100%), the 5-year RFI was 98% (95% CI, 93%-100%), the 5-year distant RFI was 100% (95% CI, 100%-100%), and the 5-year overall survival was 99% (95% CI, 97%-100%).<\/p>\n
The researchers also used a whole-genome\u2013based, tumor-informed ultrasensitive assay to assess ctDNA detection and clearance. At baseline, ctDNA was detected in 89.5% of patients (n=51), but ctDNA clearance occurred in 96.1% of these patients (n=49) after neoadjuvant therapy. Detectability remained low (<10%) during postoperative follow-up. Only one patient experienced a local recurrence, and ctDNA cleared after surgical resection.<\/p>\n
Overall, the researchers conclude that neoadjuvant THP was associated with excellent long-term outcomes for patients with early-stage ERBB2-positive breast cancer, with near-universal ctDNA clearance. However, they add that, because the sample size in this study was small, further research in larger cohorts is still needed to validate ctDNA as a prognostic biomarker in this setting.<\/p>\n","protected":false},"excerpt":{"rendered":"The neoadjuvant combination of paclitaxel, trastuzumab, and pertuzumab (THP) shows promise for treating early-stage ERBB2-positive breast cancer. However,…\n","protected":false},"author":2,"featured_media":561246,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-561245","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/561245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=561245"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/561245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/561246"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=561245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=561245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=561245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}